Human Peripheral Blood Immature Dendritic Cells, Frozen

Primary human cells, frozen

Human Peripheral Blood Immature Dendritic Cells, Frozen

Primary human cells, frozen

From: 870 USD
Catalog #
Primary human cells, frozen


Choose ready-to-use, ethically sourced, primary immature dendritic cells (DCs). With personalized service, custom products, flexible delivery times, and the option to reserve entire lots to prescreen cells for applications, we help you get the cells you need.

Immunomagnetically selected peripheral blood monocytes are cultured in RPMI 1640 Medium (Catalog #36750) + 10% FBS, GM-CSF, and IL-4 to generate immature DCs. Cells are collected using Institutional Review Board (IRB)-approved consent forms and protocols and cryopreserved in animal component-free CryoStor®CS10 medium (Catalog #07930). Additional documentation and high-resolution HLA typing (Class I and Class II alleles and CMV status) are available upon request. Acid-citrate-dextrose solution A (ACDA) is added during collection as an anticoagulant. Donor specifications (e.g. BMI category, smoking status, ethnicity, etc.) can be requested in the comment box above. Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C.

Certain products are only available in select territories. Please contact your local sales representative or Product & Scientific Support at for further information.

Browse our Frequently Asked Questions (FAQs) on Primary Cells.
• CryoStor® CS10
Cell Type
Dendritic Cells, Monocytes
Cell and Tissue Source
Peripheral Blood
Donor Status
≥ 90% CD11c+, ≥ 90% MHC class II+, ≤ 30% CD83+, and ≤ 5% CD14high by flow cytometry

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Catalog #
Lot #


This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (1)

Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells. Poulsen C et al. Toxicology letters 2015 AUG


Long-chain bases are present in the oral cavity. Previously we determined that sphingosine, dihydrosphingosine, and phytosphingosine have potent antimicrobial activity against oral pathogens. Here, we determined the cytotoxicities of long-chain bases for oral cells, an important step in considering their potential as antimicrobial agents for oral infections. This information would clearly help in establishing prophylactic or therapeutic doses. To assess this, human oral gingival epithelial (GE) keratinocytes, oral gingival fibroblasts (GF), and dendritic cells (DC) were exposed to 10.0-640.0 μM long-chain bases and glycerol monolaurate (GML). The effects of long-chain bases on cell metabolism (conversion of resazurin to resorufin), membrane permeability (uptake of propidium iodide or SYTOX-Green), release of cellular contents (LDH), and cell morphology (confocal microscopy) were all determined. GE keratinocytes were more resistant to long-chain bases as compared to GF and DC, which were more susceptible. For DC, 0.2-10.0 μM long-chain bases and GML were not cytotoxic; 40.0-80.0 μM long-chain bases, but not GML, were cytotoxic; and 80.0 μM long-chain bases induced cellular damage and death in less than 20 min. The LD50 of long-chain bases for GE keratinocytes, GF, and DC were considerably higher than their minimal inhibitory concentrations for oral pathogens, a finding important to pursuing their future potential in treating periodontal and oral infections.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.